CYP19A1 and breast carcinoma: In this study, in silico techniques including molecular docking, MM-GBSA, and molecular dynamics were employed to identify compounds with multitarget inhibitory potentiality against CDK4/6 and aromatase for the treatment of estrogen receptor-positive breast cancer.